<p>赛诺菲（纳斯达克股票代码：SNY - 获取免费报告）在周三发布的研究报告中，由 StockNews.com 的股票研究分析师将其评级从 “买入” 上调至 “强烈买入”。</p>
<ul>
<li>诺和诺德推出 Wegovy，成为三重威胁</li>
</ul>
<p>另外，Argus 将赛诺菲的股票目标价从 55.00 美元上调至 60.00 美元，并在 7 月 26 日星期五的研究报告中给予该公司 “买入” 评级。三位投资分析师对该股票进行了持有评级，两位给予买入评级，一位给予强烈买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “中等买入”，平均目标价为 57.50 美元。</p>
<p><strong>查看我们关于 SNY 的最新报告</strong></p>
<h2>赛诺菲股票表现</h2>
<ul>
<li>6 个购买辉瑞制药股票的理由</li>
</ul>
<p>赛诺菲股票周三开盘价为 56.32 美元。赛诺菲的 12 个月最低价为 42.63 美元，最高价为 56.57 美元。该公司的市值为 1426.4 亿美元，市盈率为 28.30，市盈增长比为 1.56，贝塔系数为 0.59。该企业的 50 天简单移动平均线为 51.20 美元，200 天简单移动平均线为 49.17 美元。该公司的资产负债比为 0.17，流动比率为 1.00，速动比率为 0.65。</p>
<p>赛诺菲（纳斯达克股票代码：SNY - 获取免费报告）于 7 月 25 日星期四公布了季度收益数据。该公司报告本季度每股收益为 0.93 美元，超过了 0.88 美元的共识预期 0.05 美元。本季度营收为 107.5 亿美元，低于分析师预期的 168.6 亿美元。赛诺菲的净利润率为 9.60%，净资产回报率为 26.29%。该业务的营收同比增长了 7.8%。去年同期，该公司每股收益为 0.95 美元。根据股票研究分析师的平均预期，预计赛诺菲今年将实现每股收益 4.19 美元。</p>
<h2>赛诺菲机构交易</h2>
<ul>
<li>投资的 20 个最佳医疗保健股</li>
</ul>
<p>对该公司的股票进行了买卖的对冲基金。TCTC Holdings LLC 在第一季度增持了赛诺菲股票，持股增长了 28.0%。TCTC Holdings LLC 现在拥有 960 股该公司股票，价值 47000 美元，上季度购入了额外的 210 股。HB Wealth Management LLC 在第二季度增持了赛诺菲股票，持股增长了 3.7%。HB Wealth Management LLC 现在拥有 6166 股该公司股票，价值 299000 美元，上季度购入了额外的 221 股。Wynn Capital LLC 在第一季度增持了赛诺菲股票，持股增长了 4.5%。Wynn Capital LLC 现在拥有 5266 股该公司股票，价值 256000 美元，上季度购入了额外的 226 股。Insigneo Advisory Services LLC 在第二季度增持了赛诺菲股票，持股增长了 3.3%。Insigneo Advisory Services LLC 现在拥有 7212 股该公司股票，价值 371000 美元，上季度购入了额外的 228 股。最后，Angeles Investment Advisors LLC 在第四季度增持了赛诺菲股票，持股增长了 2.1%。Angeles Investment Advisors LLC 现在拥有 12029 股该公司股票，价值 598000 美元，上季度购入了额外的 244 股。该股票的 10.04% 由对冲基金和其他机构投资者持有。</p>
<h2>赛诺菲公司简介（获取免费报告）</h2>
<p>赛诺菲是一家从事在美国、欧洲和国际市场研究、开发、生产和营销治疗方案的医疗保健公司。其业务涵盖制药、疫苗和消费者保健领域。该公司提供特殊护理，如 DUPIXENT、神经学和免疫学、罕见疾病、肿瘤学和罕见血液疾病；治疗糖尿病和心血管疾病的药物；以及已建立的处方产品。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们比赛诺菲更喜欢的五支股票</li>
<li>什么是标准普尔 500 指数，以及它与其他指数的区别</li>
<li>研究：退休人员从兼职工作中赚取多少钱？</li>
<li>市盈率计算：如何评估股票</li>
<li>Brinker International 因盈利不及预期而提供回调机会</li>
<li>对投资者最重要的沃伦·巴菲特股票：他自己的</li>
<li>Globant 是一个新兴的人工智能投资，正在扩大其业务范围</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z"/></p>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 抓住这只支付 22% 股息的 ETF（来自 Investors Alley）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDE2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDE2"/></p>
<h2>您现在是否应该投资 1000 美元购买赛诺菲股票？</h2>
<p>在考虑赛诺菲之前，您可能希望听听这个。</p>
<p>MarketBeat 追踪华尔街顶级评级和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前购买的股票...而赛诺菲不在名单上。</p>
<p>虽然赛诺菲目前在分析师中有 “持有” 评级，但顶级分析师认为这五支股票更值得购买。</p>
<p>查看这五支股票</p>

赛诺菲

<p>StockNews.com 将赛诺菲（纳斯达克股票代码：SNY）的评级从 “买入” 上调至 “强烈买入”。此外，Argus 设定了更高的目标股价，并维持了 “买入” 评级。目前，赛诺菲的平均评级为 “中等买入”，目标股价为 XX 美元。股价开盘为 XX 美元，12 个月内最低为 XX 美元，最高为 XX 美元。最近一个季度的收益每股为 XX 美元，超过了预期。分析师预测今年的每股收益为 4.19 美元。机构投资者持有该股的 10.04%</p>

<p>Sanofi (NASDAQ:SNY - Get Free Report) was upgraded by equities research analysts at StockNews.com from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note issued on Wednesday.</p>
<ul>
<li>Novo Nordisk Arms Wegovy to Be a Triple Threat</li>
</ul>
<div class="lb-trans"><p>赛诺菲（纳斯达克股票代码：SNY - 获取免费报告）在周三发布的研究报告中，由 StockNews.com 的股票研究分析师将其评级从 “买入” 上调至 “强烈买入”。</p>
<ul>
<li>诺和诺德推出 Wegovy，成为三重威胁</li>
</ul>
</div><p>Separately, Argus raised their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, July 26th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $57.50.</p>
<div class="lb-trans"><p>另外，Argus 将赛诺菲的股票目标价从 55.00 美元上调至 60.00 美元，并在 7 月 26 日星期五的研究报告中给予该公司 “买入” 评级。三位投资分析师对该股票进行了持有评级，两位给予买入评级，一位给予强烈买入评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “中等买入”，平均目标价为 57.50 美元。</p>
</div><p><strong>View Our Latest Report on SNY</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 SNY 的最新报告</strong></p>
</div><h2>Sanofi Stock Performance</h2>
<ul>
<li>6 reasons to buy Teva Pharmaceuticals stock sooner than later</li>
</ul>
<div class="lb-trans"><h2>赛诺菲股票表现</h2>
<ul>
<li>6 个购买辉瑞制药股票的理由</li>
</ul>
</div><p>Shares of SNY stock opened at $56.32 on Wednesday. Sanofi has a 12-month low of $42.63 and a 12-month high of $56.57. The firm has a market capitalization of $142.64 billion, a price-to-earnings ratio of 28.30, a price-to-earnings-growth ratio of 1.56 and a beta of 0.59. The business has a 50 day simple moving average of $51.20 and a 200 day simple moving average of $49.17. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.</p>
<div class="lb-trans"><p>赛诺菲股票周三开盘价为 56.32 美元。赛诺菲的 12 个月最低价为 42.63 美元，最高价为 56.57 美元。该公司的市值为 1426.4 亿美元，市盈率为 28.30，市盈增长比为 1.56，贝塔系数为 0.59。该企业的 50 天简单移动平均线为 51.20 美元，200 天简单移动平均线为 49.17 美元。该公司的资产负债比为 0.17，流动比率为 1.00，速动比率为 0.65。</p>
</div><p>Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to analysts' expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The business's revenue was up 7.8% on a year-over-year basis. During the same period last year, the firm posted $0.95 earnings per share. On average, equities research analysts anticipate that Sanofi will post 4.19 EPS for the current year.</p>
<div class="lb-trans"><p>赛诺菲（纳斯达克股票代码：SNY - 获取免费报告）于 7 月 25 日星期四公布了季度收益数据。该公司报告本季度每股收益为 0.93 美元，超过了 0.88 美元的共识预期 0.05 美元。本季度营收为 107.5 亿美元，低于分析师预期的 168.6 亿美元。赛诺菲的净利润率为 9.60%，净资产回报率为 26.29%。该业务的营收同比增长了 7.8%。去年同期，该公司每股收益为 0.95 美元。根据股票研究分析师的平均预期，预计赛诺菲今年将实现每股收益 4.19 美元。</p>
</div><h2>Institutional Trading of Sanofi</h2>
<ul>
<li>20 best healthcare dividend stocks to invest in</li>
</ul>
<div class="lb-trans"><h2>赛诺菲机构交易</h2>
<ul>
<li>投资的 20 个最佳医疗保健股</li>
</ul>
</div><p>Hedge funds have recently bought and sold shares of the company. TCTC Holdings LLC grew its holdings in shares of Sanofi by 28.0% during the first quarter. TCTC Holdings LLC now owns 960 shares of the company's stock valued at $47,000 after buying an additional 210 shares in the last quarter. HB Wealth Management LLC grew its stake in Sanofi by 3.7% during the 2nd quarter. HB Wealth Management LLC now owns 6,166 shares of the company's stock valued at $299,000 after acquiring an additional 221 shares in the last quarter. Wynn Capital LLC increased its holdings in shares of Sanofi by 4.5% in the 1st quarter. Wynn Capital LLC now owns 5,266 shares of the company's stock valued at $256,000 after purchasing an additional 226 shares during the period. Insigneo Advisory Services LLC lifted its position in shares of Sanofi by 3.3% in the second quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company's stock worth $371,000 after purchasing an additional 228 shares in the last quarter. Finally, Angeles Investment Advisors LLC boosted its holdings in shares of Sanofi by 2.1% during the fourth quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company's stock worth $598,000 after purchasing an additional 244 shares during the period. 10.04% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对该公司的股票进行了买卖的对冲基金。TCTC Holdings LLC 在第一季度增持了赛诺菲股票，持股增长了 28.0%。TCTC Holdings LLC 现在拥有 960 股该公司股票，价值 47000 美元，上季度购入了额外的 210 股。HB Wealth Management LLC 在第二季度增持了赛诺菲股票，持股增长了 3.7%。HB Wealth Management LLC 现在拥有 6166 股该公司股票，价值 299000 美元，上季度购入了额外的 221 股。Wynn Capital LLC 在第一季度增持了赛诺菲股票，持股增长了 4.5%。Wynn Capital LLC 现在拥有 5266 股该公司股票，价值 256000 美元，上季度购入了额外的 226 股。Insigneo Advisory Services LLC 在第二季度增持了赛诺菲股票，持股增长了 3.3%。Insigneo Advisory Services LLC 现在拥有 7212 股该公司股票，价值 371000 美元，上季度购入了额外的 228 股。最后，Angeles Investment Advisors LLC 在第四季度增持了赛诺菲股票，持股增长了 2.1%。Angeles Investment Advisors LLC 现在拥有 12029 股该公司股票，价值 598000 美元，上季度购入了额外的 244 股。该股票的 10.04% 由对冲基金和其他机构投资者持有。</p>
</div><h2>Sanofi Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>赛诺菲公司简介（获取免费报告）</h2>
</div><p>Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.</p>
<div class="lb-trans"><p>赛诺菲是一家从事在美国、欧洲和国际市场研究、开发、生产和营销治疗方案的医疗保健公司。其业务涵盖制药、疫苗和消费者保健领域。该公司提供特殊护理，如 DUPIXENT、神经学和免疫学、罕见疾病、肿瘤学和罕见血液疾病；治疗糖尿病和心血管疾病的药物；以及已建立的处方产品。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Sanofi</li>
<li>What is the S&amp;P 500 and How It is Distinct from Other Indexes</li>
<li>Study: How Much Are Retirees Earning from Side Hustles in 2024?</li>
<li>P/E Ratio Calculation: How to Assess Stocks</li>
<li>Brinker International Offers a Pullback Opportunity on EPS Miss</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Globant Is an Emerging AI Play That’s Expanding Its Footprint</li>
</ul>
<div class="lb-trans"><h2>进一步阅读</h2>
<ul>
<li>我们比赛诺菲更喜欢的五支股票</li>
<li>什么是标准普尔 500 指数，以及它与其他指数的区别</li>
<li>研究：退休人员从兼职工作中赚取多少钱？</li>
<li>市盈率计算：如何评估股票</li>
<li>Brinker International 因盈利不及预期而提供回调机会</li>
<li>对投资者最重要的沃伦·巴菲特股票：他自己的</li>
<li>Globant 是一个新兴的人工智能投资，正在扩大其业务范围</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=SNY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Grab this ETF paying a huge 22% dividend (From Investors Alley)(Ad)</p>
<div class="lb-trans"><p>→ 抓住这只支付 22% 股息的 ETF（来自 Investors Alley）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MDE2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9016&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Sanofi right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1000 美元购买赛诺菲股票？</h2>
</div><p>Before you consider Sanofi, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑赛诺菲之前，您可能希望听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街顶级评级和表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五支顶级分析师悄悄告诉客户在更广泛市场注意之前购买的股票...而赛诺菲不在名单上。</p>
</div><p>While Sanofi currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然赛诺菲目前在分析师中有 “持有” 评级，但顶级分析师认为这五支股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五支股票</p>
</div>

StockNews.com 将赛诺菲（NASDAQ:SNY）的评级上调至强力买入